Concepedia

Victor Sandor

VS

Statistics

Publications

35

Citations

8K

H-Index

27

Active since

1992

Affiliations

Incyte (United States)(Current)

The University of Texas MD Anderson Cancer Center

Mayo Clinic in Arizona

Princess Margaret Cancer Centre

University of Toronto

Victor Sandor is an author at Incyte (United States) specializing in medicine, pharmacology, and clinical pharmacology.

Publications per year

1992–2022

35

Publications

35

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

, , +12

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

, , +17

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 1K citations · Full text

, , +11

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 586 citations

, , +11

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Victor Sandor, Susan Bakke, Robert W. Robey et al. · PubMed · 2002 · 510 citations

, , +12

1–5 of 35